CrystecPharma signed a letter of understanding with Iconovo to develop innovative dry powder inhaler solutions for the treatment of…
Articles by Alberto Molano, PhD
The demographic and clinical characteristics of patients with idiopathic pulmonary fibrosis (IPF) in Spain are similar to those of…
Gli proteins can trigger fibroblast activation and support their role in promoting fibrosis in the lungs in response to damage…
Lung Therapeutics announced that it has raised $36 million in Series C financing to fund two projects, including…
Measuring three specific biomarkers — nitric oxide, PGE2, and 8‐isoprostane — in the exhaled breath condensates (EBC) or bronchoalveolar lavage…
A long-term collaboration was announced to accelerate the discovery of new medicines for idiopathic pulmonary fibrosis (IPF) and chronic…
Algernon Pharmaceuticals announced its plans to conduct a new in vivo animal study comparing its lead anti-fibrotic NP-251 compound with clinically relevant…
The incidence of lung cancer is greater among patients with idiopathic pulmonary fibrosis (IPF), compared with the general population, and…